Silence Therapeutics plc (NASDAQ:SLN) is M28 Capital Management LP’s 6th Largest Position

M28 Capital Management LP lowered its position in Silence Therapeutics plc (NASDAQ:SLN) by 38.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 185,100 shares of the company’s stock after selling 114,300 shares during the quarter. Silence Therapeutics comprises about 4.6% of M28 Capital Management LP’s portfolio, making the stock its 6th largest position. M28 Capital Management LP owned 0.62% of Silence Therapeutics worth $3,517,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC raised its position in Silence Therapeutics by 10.5% in the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after purchasing an additional 667 shares during the period. Custom Index Systems LLC purchased a new stake in shares of Silence Therapeutics in the second quarter worth approximately $282,000. Legato Capital Management LLC bought a new stake in shares of Silence Therapeutics during the 2nd quarter worth approximately $376,000. Nicholas Investment Partners LP purchased a new position in Silence Therapeutics during the 2nd quarter valued at $2,859,000. Finally, Parkman Healthcare Partners LLC boosted its holdings in Silence Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,063 shares during the period. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Price Performance

Shares of Silence Therapeutics stock opened at $18.27 on Friday. The firm’s 50-day moving average is $18.62 and its two-hundred day moving average is $20.52. Silence Therapeutics plc has a 1 year low of $6.15 and a 1 year high of $27.72. The stock has a market cap of $546.78 million, a price-to-earnings ratio of -15.75 and a beta of 1.29.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10). The firm had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $11.28 million. Silence Therapeutics had a negative return on equity of 58.28% and a negative net margin of 222.44%. On average, equities analysts expect that Silence Therapeutics plc will post -1.55 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on SLN. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, August 30th. Morgan Stanley lifted their price objective on shares of Silence Therapeutics from $45.00 to $49.00 and gave the company an “overweight” rating in a report on Friday, June 28th. Chardan Capital restated a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a research note on Friday, August 16th. Finally, Jefferies Financial Group began coverage on shares of Silence Therapeutics in a research note on Tuesday, September 3rd. They set a “buy” rating and a $40.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $57.20.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.